semaglutide heart failure fda US approves weight loss drug Wegovy to prevent cardiovascular events FDA approves weight loss drug
Description
Based on a systematic synthesis of available findings, we conclude that there is considerable support for the neuromodulatory potential of gut-based circulating peptides on reward responses
Long-term semaglutide use for weight management shows generally favorable safety data in clinical trials, though individual outcomes depend on baseline health status, existing conditions, and genetic predispositions
Compare the top GLP-1 telehealth programs for weight loss
doi:10.3390/ijms24021703 Contributor A
